ST香雪(300147)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300147 ST香雪

已收盘 03-23 15:00:00

{"stockData":{"symbol":"300147","market":"SZ","secType":"STK","nameCN":"ST香雪","latestPrice":8.87,"timestamp":1774249437000,"preClose":9.31,"halted":0,"volume":10149540,"delay":0,"changeRate":-0.0473,"floatShares":657000000,"shares":661000000,"eps":-1.5163,"marketStatus":"已收盘","change":-0.44,"latestTime":"03-23 15:00:00","open":9.16,"high":9.23,"low":8.71,"amount":91758500,"amplitude":0.0559,"askPrice":8.87,"askSize":994,"bidPrice":8.86,"bidSize":1127,"shortable":0,"etf":0,"ttmEps":-1.5163,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":9.31,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":9.78,"lowLimit":8.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":661279045,"isCdr":false,"pbRate":8.89,"roa":"--","roe":"--","epsLYR":-1.3,"committee":0.192005,"marketValue":5866000000,"turnoverRate":0.0154,"status":1,"floatMarketCap":5831000000},"requestUrl":"/m/hq/s/300147","defaultTab":"news","newsList":[{"id":"2613794501","title":"ST香雪（300147）披露申请借款重组公告，2月24日股价下跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613794501?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:51","pubTimestamp":1771926687,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，ST香雪报收于9.48元，较前一交易日下跌0.84%，最新总市值为62.69亿元。该股当日开盘9.79元，最高9.89元，最低9.46元，成交额达1.02亿元，换手率为1.62%。近日，ST香雪披露《关于申请借款重组的公告》。上述事项已获董事会审议通过，担保金额在2024年度股东会审批额度内，无需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0070","BK0239","BK0028","300147"],"gpt_icon":0},{"id":"2611484178","title":"ST香雪新注册《香雪数字化营销系统（小程序）V2.2.4》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2611484178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611484178?lang=zh_cn&edition=full","pubTime":"2026-02-16 01:38","pubTimestamp":1771177094,"startTime":"0","endTime":"0","summary":"证券之星消息，近日ST香雪（300147）新注册了《香雪数字化营销系统（小程序）V2.2.4》项目的软件著作权。今年以来ST香雪新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了3341.43万元，同比减5.49%。通过天眼查大数据分析，广州市香雪制药股份有限公司共对外投资了40家企业，参与招投标项目2190次；财产线索方面有商标信息358条，专利信息168条，著作权信息21条；此外企业还拥有行政许可249个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021600000033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300147","BK0239","BK0028","BK0060"],"gpt_icon":0},{"id":"2611584131","title":"ST香雪(300147.SZ)：申请借款重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2611584131","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611584131?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:07","pubTimestamp":1770970023,"startTime":"0","endTime":"0","summary":"格隆汇2月13日丨ST香雪公布，根据业务发展需要，广州市香雪制药股份有限公司向广东南海农村商业银行股份有限公司申请不超过人民币3.69亿元借款重组，期限一年，用于公司的经营生产发展。本次担保事项属于以公司全资子公司及公司自身的资产为公司提供担保，全资子公司广州香岚健康产业有限公司已履行了内部审议程序同意继续为重组借款提供担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260213/32017409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300147","BK0028","BK0070","BK0239","BK0060"],"gpt_icon":0},{"id":"2609157572","title":"ST香雪最新公告：公司及子公司累计涉及诉讼金额9226.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609157572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609157572?lang=zh_cn&edition=full","pubTime":"2026-02-08 18:10","pubTimestamp":1770545426,"startTime":"0","endTime":"0","summary":"ST香雪(300147.SZ)公告称，公司及子公司连续十二个月内作为被告累计涉及的诉讼事项涉案金额合计约9226.56万元，占最近一期经审计净资产8.78%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800008722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300147","BK0060","BK0028","BK0070"],"gpt_icon":0},{"id":"2608788932","title":"股市必读：ST香雪（300147）预计2025年全年扣非后净利润亏损6.12亿元至8.99亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608788932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608788932?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:10","pubTimestamp":1769973022,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，ST香雪报收于9.44元，下跌0.11%，换手率1.44%，成交量9.47万手，成交额8926.73万元。ST香雪发布业绩预告，预计2025年全年归属净利润亏损6.35亿元至9.34亿元。公司公告汇总2025年度业绩预告广州市香雪制药股份有限公司预计2025年度归属于上市公司股东的净利润亏损63,519万元至93,410万元，上年同期亏损85,856万元。扣除非经常性损益后的净利润亏损61,160万元至89,942万元。最终数据以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300147"],"gpt_icon":0},{"id":"2607019503","title":"ST香雪：预计2025年全年扣非后净利润亏损6.12亿元至8.99亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607019503","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607019503?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:19","pubTimestamp":1769768376,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪发布业绩预告，预计2025年全年扣非后净利润亏损6.12亿元至8.99亿元。ST香雪2025年三季报显示，前三季度公司主营收入11.46亿元，同比下降25.28%；归母净利润-3.62亿元，同比下降66.16%；扣非净利润-3.11亿元，同比下降51.66%；其中2025年第三季度，公司单季度主营收入3.28亿元，同比下降24.96%；单季度归母净利润-1.28亿元，同比下降55.04%；单季度扣非净利润-1.04亿元，同比下降7.23%；负债率85.08%，投资收益45.19万元，财务费用2.04亿元，毛利率31.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000034247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300147"],"gpt_icon":0},{"id":"2603960778","title":"ST香雪：子公司获两项癌症治疗临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2603960778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603960778?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:52","pubTimestamp":1768481527,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：103实验什么样，都基因病治疗效果ST香雪回复：您好，感谢对公司的关注。2025年12月，公司子公司生命科学收到了国家药品监督管理局签发的两份《药物临床试验批准通知书》，获批适应症分别为：用于治疗基因型为HLA-A*11:01，肿瘤新生抗原KRAS G12V突变阳性的晚期非小细胞肺癌；用于治疗基因型为HLA-A*11:01，肿瘤新生抗原KRAS G12V突变阳性的晚期胰腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500038813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0028","BK0060","300147"],"gpt_icon":0},{"id":"2602512793","title":"ST香雪（300147）新增【粤港澳】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602512793?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:30","pubTimestamp":1768221021,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，1月12日ST香雪新增概念。新增概念原因：公司办公地址为：广东省广州市黄埔区广州开发区科学城金峰园路2号。该公司关联的其它概念板块还包括：辅助生殖、口罩防护、创新药、免疫治疗。ST香雪主营业务：现代中药及中药饮片的研发、生产与销售,辅之医疗器械、软饮料、少量西药产品及医药流通等业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200033692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0060","BK0070","300147"],"gpt_icon":0},{"id":"2594234750","title":"ST香雪：子公司新药研发按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2594234750","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594234750?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:48","pubTimestamp":1766666896,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：近日新版医保、商保刚新增了35款抗癌药和13种天价疗法，肺癌等这些癌种的用药保障一下变扎实了，感觉对咱们创新药企是波不错的利好！公司在研的TAEST16001和1901注射液都覆盖这些癌种，会不会借着这波政策东风，加快推进这俩产品的临床节奏呀？公司子公司新药的研发会根据公司实际情况及研发计划推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0060","300147","BK0028","BK0239"],"gpt_icon":0},{"id":"2594723420","title":"ST香雪：预重整目前在审计、评估阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2594723420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594723420?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:48","pubTimestamp":1766666890,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪(300147)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司预重整工作长期停滞在审计，评估阶段。已经不像是想通过重整来化解债务风险，促进企业发展的一个公司，给人的感觉是在摆烂。预重整工作这么长时间没有进展的主要原因在哪里？ST香雪回复：您好，感谢对公司的关注。公司预重整目前在审计、评估阶段，会积极配合临时管理人的工作推进。相关进展情况，公司会按照信息披露规则结合实际情况以公告的形式对外披露，请您留意公司公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0060","BK0239","BK0028","300147"],"gpt_icon":0},{"id":"2593475949","title":"ST香雪（300147）披露XLS-103注射液获得药物临床试验批准，12月24日股价上涨0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475949","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475949?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:51","pubTimestamp":1766569919,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，ST香雪报收于9.51元，较前一交易日上涨0.21%，最新总市值为62.89亿元。该股当日开盘9.71元，最高9.79元，最低9.5元，成交额达8545.52万元，换手率为1.35%。近日，ST香雪发布公告称，公司子公司香雪生命科学技术（广东）有限公司收到国家药品监督管理局签发的两份《药物临床试验批准通知书》，XLS-103注射液获准开展用于治疗基因型为HLA-A*11:01、肿瘤新生抗原KRAS G12V突变阳性的晚期非小细胞肺癌和晚期胰腺癌的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400029094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300147","BK0239","BK0070","BK0028"],"gpt_icon":0},{"id":"2593499629","title":"ST香雪最新公告：XLS-103注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593499629","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593499629?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:10","pubTimestamp":1766484623,"startTime":"0","endTime":"0","summary":"ST香雪公告称，公司子公司香雪生命科学的XLS-103注射液新药临床注册申请获得临床试验许可，用于治疗基因型为HLA-A*11:01，肿瘤新生抗原KRAS G12V突变阳性的晚期非小细胞肺癌和晚期胰腺癌。这是香雪生命科学基于现有的TCR-T细胞治疗核心技术和研发平台获得的第六个和第七个关于TCR-T产品的《临床试验通知书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300030064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300147","BK0239","BK0070","BK0028"],"gpt_icon":0},{"id":"2588620046","title":"ST香雪：橘红痰咳液将启动慢阻肺临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2588620046","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588620046?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:48","pubTimestamp":1764766105,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪12月02日在投资者关系平台上答复投资者关心的问题。新药研发的进展会按照信披规则结合实际情况对外披露，请您留意公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300147","BK0070","BK0060","BK0028","BK0239"],"gpt_icon":0},{"id":"2588053325","title":"ST香雪：预重整处于审计评估阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588053325?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:52","pubTimestamp":1764679979,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪12月02日在投资者关系平台上答复投资者关心的问题。公司预重整目前在审计、评估阶段，重整的方案暂未制定，公司会积极配合临时管理人的工作推进。基于信息披露规则要求，相关的进展情况，公司会按照信息披露规则结合实际情况以公告的形式对外披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200036950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300147","BK0060","BK0028","BK0070","BK0239"],"gpt_icon":0},{"id":"2583250355","title":"ST香雪：公司重视TAEST16001的临床价值与市场潜力 正全力推进确证性临床试验筹备阶段的工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2583250355","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583250355?lang=zh_cn&edition=full","pubTime":"2025-11-14 12:46","pubTimestamp":1763095560,"startTime":"0","endTime":"0","summary":"　　每经AI快讯，有投资者在投资者互动平台提问：贵司TAEST16001确证性临床早就已获CDE方案认可，而广生堂、常山药业等同行首例入组均及时公告。这是公司核心资产，投资者有权知情！ST香雪（维权）11月14日在投资者互动平台表示，公司高度重视TAEST16001的临床价值与市场潜力，正全力推进确证性临床试验筹备阶段的工作。新药研发现阶段的进展情况，前期已披露，后续会根据临床情况结合信息披露规则以公告的形式对外披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxiwfe3145620.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxiwfe3145620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300147","BK0070","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2583605965","title":"ST香雪：公司预重整目前在审计、评估阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2583605965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583605965?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:48","pubTimestamp":1763038118,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司预重整阶段是否已有明确的意向投资方接触并开展尽调？公司在引入投资方时，是否会优先考虑能为TCR-T管线提供研发资金支持或商业化渠道资源的产业资本？ST香雪回复：您好，感谢对公司的关注。公司预重整，目前在审计、评估阶段。公司会积极配合临时管理人的工作，按照信息披露规则结合实际情况以公告的形式对外披露，请您留意公司公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300147","BK0239","BK0060","BK0028"],"gpt_icon":0},{"id":"2583560548","title":"ST香雪：TAEST16001获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560548","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583560548?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:48","pubTimestamp":1763038115,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪(300147)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司16001注射液新增的2个适应症，分别是晚期食道癌、晚期非小细胞肺癌，并且获得了临床试验许可。请问这2个新增的适应症是处于二期临床试验阶段吗？ST香雪回复：您好，感谢对公司的关注。TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，均已获得临床试验批准，暂未开展临床试验。后续研发进展会按照信息披露规则结合实际情况以公告的形式对外披露。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300147","BK0060","BK0028","BK0070","BK0239"],"gpt_icon":0},{"id":"2579464729","title":"ST香雪：后续将结合实际情况组织交流会","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579464729?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:52","pubTimestamp":1761915172,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪10月31日在投资者关系平台上答复投资者关心的问题。投资者提问：投资者多次追问TAEST16001确证性临床的入组进度、数据节点，公司回复偏笼统，而信达生物等同类企业会主动披露关键信息以稳信心、撑股价。基于信披规则，公司新药研发的进展都是以公告的形式对外披露，后续会结合实际情况组织相关的交流会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100047264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300147","BK0060","BK0028","BK0070"],"gpt_icon":0},{"id":"2579464122","title":"ST香雪：TAEST1901注射液晚期肝癌I期临床研究暂未完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579464122?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:48","pubTimestamp":1761914926,"startTime":"0","endTime":"0","summary":"证券之星消息，ST香雪(300147)10月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的TAEST1901注射液针对晚期肝癌的一期临床试验目前进展如何？是否已经完成？ST香雪回复：您好，感谢对公司的关注。TAEST1901注射液，适应症为晚期肝癌，在I期临床研究中，暂未完成。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100047069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0060","300147","BK0070"],"gpt_icon":0},{"id":"2578939177","title":"ST香雪(300147)9月30日股东户数3.5万户，较上期减少14.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578939177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578939177?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:38","pubTimestamp":1761644309,"startTime":"0","endTime":"0","summary":"证券之星消息，近日ST香雪披露，截至2025年9月30日公司股东户数为3.5万户，较6月30日减少5867.0户，减幅为14.36%。在中药行业个股中，ST香雪股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.36万户。从股价来看，2025年6月30日至2025年9月30日，ST香雪区间涨幅为23.2%，在此期间股东户数减少5867.0户，减幅为14.36%。根据统计，ST香雪2025年6月30日至2025年9月30日，主力资金净流出7.54亿元，游资资金净流入1.79亿元，散户资金净流入5.74亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800032105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0070","300147"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774291904482,"stockEarnings":[{"period":"1week","weight":-0.0624},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0653},{"period":"6month","weight":-0.2066},{"period":"1year","weight":-0.1148},{"period":"ytd","weight":-0.0253}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州市香雪制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34981人(较上一季度减少14.36%)","perCapita":"18793股","listingDate":"2010-12-15","address":"广东省广州市黄埔区广州开发区科学城金峰园路2号(自编第一、二、三、四、五、六、七、八栋)","registeredCapital":"66127万元","survey":"　　广州市香雪制药股份有限公司的主营业务是现代中药饮片的研发、生产与销售，辅之医疗器械、少量西药产品及医药流通等业务。公司的主要产品是中药饮片、医疗器械、西药产品。","listedPrice":33.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST香雪(300147)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST香雪(300147)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST香雪,300147,ST香雪股票,ST香雪股票老虎,ST香雪股票老虎国际,ST香雪行情,ST香雪股票行情,ST香雪股价,ST香雪股市,ST香雪股票价格,ST香雪股票交易,ST香雪股票购买,ST香雪股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST香雪(300147)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST香雪(300147)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}